Therapeutic Resistance to Anti-hormonal Drugs in Breast Cancer (eBook)

New Molecular Aspects and their Potential as Targets
eBook Download: PDF
2009 | 2009
XII, 204 Seiten
Springer Netherlands (Verlag)
978-1-4020-8526-0 (ISBN)

Lese- und Medienproben

Therapeutic Resistance to Anti-hormonal Drugs in Breast Cancer -
Systemvoraussetzungen
149,79 inkl. MwSt
  • Download sofort lieferbar
  • Zahlungsarten anzeigen

One of the main causes of failure in the treatment of breast cancer is the intrinsic presence of, or development of, drug resistance by the cancer cells. Recent studies on the mechanisms of cancer drug resistance have yielded important information highlighting both how tumour cells may escape these therapeutic constraints and that drug resistance may further impinge on tumour cell functions that may ultimately promote an adverse cell phenotype. New targets have been identified with potential therapeutic applications in resistant breast cancer leading to the subsequent evaluation of inhibitors of these targets in preclinical studies. Importantly, there is increasing evidence from such studies demonstrating the benefit of novel combination strategies as potential avenues for future drug regimens.

Written by experts in the subject area, this book covers the molecular details and functional consequences of endocrine resistance in breast cancer with particular emphasis on the future applications of novel drug combinations that may be utilized to circumvent resistance and improve anti-tumour effects. This book represents a timely publication in the field of breast cancer research, providing current knowledge in the area of drug resistance and will be important reading material for clinicians and researchers alike.


One of the main causes of failure in the treatment of breast cancer is the intrinsic presence of, or development of, drug resistance by the cancer cells. Recent studies on the mechanisms of cancer drug resistance have yielded important information highlighting both how tumour cells may escape these therapeutic constraints and that drug resistance may further impinge on tumour cell functions that may ultimately promote an adverse cell phenotype. New targets have been identified with potential therapeutic applications in resistant breast cancer leading to the subsequent evaluation of inhibitors of these targets in preclinical studies. Importantly, there is increasing evidence from such studies demonstrating the benefit of novel combination strategies as potential avenues for future drug regimens.Written by experts in the subject area, this book covers the molecular details and functional consequences of endocrine resistance in breast cancer with particular emphasis on the future applications of novel drug combinations that may be utilized to circumvent resistance and improve anti-tumour effects. This book represents a timely publication in the field of breast cancer research, providing current knowledge in the area of drug resistance and will be important reading material for clinicians and researchers alike.

Part 1: OVERVIEW. 1.1 Endocrine resistance in clinical breast cancer; John F Robertson. 1.2 Endocrine resistance in experimental breast cancer; Robert I Nicholson. Part 2: NEW THEMES IN ENDOCRINE RESISTANCE. 2.1 Co-activators / co-repressors and endocrine resistance; Simak Ali. 2.2 Antihormone-induced gene changes: consequences for the development of drug-resistance; Julia Gee. 2.3 Altered signal transduction pathways: impact on ER signalling and expression; Dorraya El-Ashry. 2.4 Epigenetic alterations in DNA methylation in breast cancer; Martin Widschwendter and Heidi Fiegl. 2.5 Antihormone-induced tumour progression; Stephen Hiscox. 2.6 Influence of the tumour microenvironment; Rosemary Walker.2.7 Stem cells; Rob Clarke. Part 3: NEW ADVANCES AND INNOVATIVE THERAPEUTIC APPROACHES. 3.1 DNA profiling; Dennis Slamon. 3.2 Synthetic lethal approaches to target gene discovery; Alan Ashworth. 3.3 Intelligent combination therapies; Stephen Johnston. 3.4 Novel targeting approaches; Paul Workman. 3.5 Future treatment of endocrine-resistant breast cancer: how basic science can guide clinical development; Elizabeth Anderson.

Erscheint lt. Verlag 11.1.2009
Zusatzinfo XII, 204 p.
Verlagsort Dordrecht
Sprache englisch
Themenwelt Medizin / Pharmazie Medizinische Fachgebiete Onkologie
Medizinische Fachgebiete Radiologie / Bildgebende Verfahren Radiologie
Medizin / Pharmazie Studium
Schlagworte Breast Cancer • Cell • DNA • hormones • methylation • therapy • Tumor
ISBN-10 1-4020-8526-5 / 1402085265
ISBN-13 978-1-4020-8526-0 / 9781402085260
Haben Sie eine Frage zum Produkt?
PDFPDF (Wasserzeichen)
Größe: 4,2 MB

DRM: Digitales Wasserzeichen
Dieses eBook enthält ein digitales Wasser­zeichen und ist damit für Sie persona­lisiert. Bei einer missbräuch­lichen Weiter­gabe des eBooks an Dritte ist eine Rück­ver­folgung an die Quelle möglich.

Dateiformat: PDF (Portable Document Format)
Mit einem festen Seiten­layout eignet sich die PDF besonders für Fach­bücher mit Spalten, Tabellen und Abbild­ungen. Eine PDF kann auf fast allen Geräten ange­zeigt werden, ist aber für kleine Displays (Smart­phone, eReader) nur einge­schränkt geeignet.

Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen dafür einen PDF-Viewer - z.B. den Adobe Reader oder Adobe Digital Editions.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen dafür einen PDF-Viewer - z.B. die kostenlose Adobe Digital Editions-App.

Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.

Mehr entdecken
aus dem Bereich

von Marija Pinto

eBook Download (2023)
Urban & Fischer Verlag - Lehrbücher
26,99